H-R^MFPNAPYL-OH

Rif. 3D-PP49836

Informazioni sul prodotto

• Nome: H-R^MFPNAPYL-OH

Descrizione

Peptide H-R^MFPNAPYL-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-R^MFPNAPYL-OH include the following: The antitumor activity of TCR-mimic antibody-drug conjugates (TCRm-ADCs) targeting the intracellular wilms tumor 1 (WT1) oncoprotein Y Shen, YM Li, JJ Zhou, Z Zhou , YC Xu - International Journal of , 2019 - mdpi.comhttps://www.mdpi.com/1422-0067/20/16/3912 An In Vivo Screen to Identify Short Peptide Mimotopes with Enhanced Antitumor Immunogenicity X He , S Zhou , B Quinn, D Jahagirdar , J Ortega - Cancer immunology , 2022 - AACRhttps://aacrjournals.org/cancerimmunolres/article-abstract/10/3/314/681732 Understanding CD8+ T-cell responses toward the native and alternate HLA-A∗02:01-restricted WT1 epitope THO Nguyen , ACL Tan, SD Xiang - Clinical & , 2017 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1038/cti.2017.4 Antitumor effect of oral cancer vaccine with Bifidobacterium delivering WT1 protein to gut immune system is superior to WT1 peptide vaccine T Shirakawa , K Kitagawa - Human Vaccines & Immunotherapeutics, 2018 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1080/21645515.2017.1382787 An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A* 02: 01 and HLA-A* 24: 02 molecules T Dao, T Korontsvit, V Zakhaleva, C Jarvis - , 2017 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1080/2162402X.2016.1252895 A TCR mimic monoclonal antibody for the HPV-16 E7-epitope p11-19/HLA-A* 02: 01 complex T Dao, S Mun, T Korontsvit, AG Khan, MA Pohl, T White - Plos one, 2022 - journals.plos.orghttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0265534 A dual-receptor T-cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML T Dao, G Xiong, SS Mun, J Meyerberg, T Korontsvit - Blood, 2024 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/143/6/507/506498 Prospective identification of cross-reactive human peptide-MHC ligands for T cell receptor based therapies RS Gejman , MG Klatt , A Chang , HF Jones, CY Oh - BioRxiv, 2018 - biorxiv.orghttps://www.biorxiv.org/content/10.1101/267047.abstract Identification of the targets of T-cell receptor therapeutic agents and cells by use of a high-throughput genetic platform RS Gejman , HF Jones, MG Klatt , AY Chang - Cancer immunology , 2020 - AACRhttps://aacrjournals.org/cancerimmunolres/article-abstract/8/5/672/470110 Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential Q Zhao , M Ahmed, DV Tassev, A Hasan , TY Kuo - Leukemia, 2015 - nature.comhttps://www.nature.com/articles/leu2015125 Development of a T-cell receptor mimic antibody targeting a novel Wilms tumor 1-derived peptide and analysis of its specificity N Kurosawa, A Midorikawa, K Ida, YW Fudaba - Cancer , 2020 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1111/cas.14602 Generation and expression of high affinity, tumor antigen-specific mouse and human T cell receptors to genetically modify CD8 (+) T cells for adoptive ML Dossett - 2006 - search.proquest.comhttps://search.proquest.com/openview/e15a6c0fb38ba9554ef38793b6bb4bcb/1?pq-origsite=gscholar&cbl=18750&diss=y An input-controlled model system for identification of MHC bound peptides enabling laboratory comparisons of immunopeptidome experiments MG Klatt , ZEH Aretz , M Curcio, RS Gejman - Journal of , 2020 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S187439192030289X An essential role of the avidity of T-cell receptor in differentiation of self-antigen-reactive CD8+ T cells K Kondo, F Fujiki, H Nakajima - Journal of , 2016 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/fulltext/2016/04000/an_essential_role_of_the_avidity_of_t_cell.3.aspx Opposite effects of endogenous peptide-MHC class I on T cell activity in the presence and absence of CD8 JD Stone , DH Aggen , AS Chervin - The Journal of , 2011 - journals.aai.orghttps://journals.aai.org/jimmunol/article/186/9/5193/84974 Escherichia coli expressing recombinant WT1 protein and listeriolysin O stimulate antigen-specific T cells following vaccination in C57BL/6 mice. J Nitcheu, FS Ramirez-Jimenez, HJ Stauss, G Vassaux - 2004 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/104/11/4289/73464 Comprehensive mutagenesis identifies the peptide repertoire of a p53 T-cell receptor mimic antibody that displays no toxicity in mice transgenic for human HLA-A I Trenevska, AP Anderson, C Bentley, T Hassanali - Plos one, 2021 - journals.plos.orghttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0249967 High Avidity HLA-A2-Restricted CD8+ T Cells against the Wilms Tumor Protein (WT1) Can Be Isolated Only from HLA-A2 Negative Donors Not Subjected to HLA-A2 I Jedema, M van de Meent, WJJ Falkenburg - Blood, 2008 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0006497119511855 A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer HG Rammensee , KH Wiesmuller, PA Chandran - for immunotherapy of , 2019 - Springerhttps://link.springer.com/article/10.1186/s40425-019-0796-5 Wilms tumor 1 protein is highly expressed on malignant plasma cells and provides a novel target for immunotherapeutic approaches G Koehne, S Kosuri, E Doubrovina, T Dao, A Scott - 2015 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/126/23/98/136288 Galinpepimut-S, a Wilms' tumor protein 1 (WT1)-targeting immuno-oncology treatment, induces specific, robust, and durable immune responses (IRs) in patients G Koehne, S Devlin , N Korde, S Mailankody , H Landau - researchgate.nethttps://www.researchgate.net/profile/Nicholas-Sarlis/publication/333699864_Galinpepimut-S_a_Wilms'_tumor_protein_1_WT1-targeting_immuno-oncology_treatment_induces_specific_robust_and_durable_immune_responses_IRs_in_patients_with_high-risk_HR_multiple_myeloma_MM/links/5cffb0184585157d15a2344b/Galinpepimut-S-a-Wilms-tumor-protein-1-WT1-targeting-immuno-oncology-treatment-induces-specific-robust-and-durable-immune-responses-IRs-in-patients-with-high-risk-HR-multiple-myeloma-MM.pdf The physiological interactome of TCR-like antibody therapeutics in human tissues E Marrer-Berger, A Nicastri, A Augustin - Nature , 2024 - nature.comhttps://www.nature.com/articles/s41467-024-47062-5 In Vivo Eradication of Human Clonigenic Acute Lymphoblastic Leukemic Cells Expressing the Wilms Tumor Protein, WT-1, by HLA Restricted WT-1 Specific T-Cells in E Doubrovina, M Doubrovin , E Kanaeva, RJ O'Reilly - Blood, 2007 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0006497119868295 Generation and use of HLA-A2-restricted, peptide-specific monoclonal antibodies and chimeric antigen receptors DV Tassev - 2011 - mskcc.orghttps://www.mskcc.org/sites/default/files/node/165658/document/final-dimiter-tassev.pdf A Cytotoxic Human Monoclonal Antibody Recognizing Cell Surface WT1 Peptide/HLA-A2 Complexes DA Scheinberg, T Dao, S Yan, L Zhou, T Korontsvit - 2011 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/118/21/1677/139829 Specificity of bispecific T cell receptors and antibodies targeting peptide-HLA CJ Holland, RM Crean , JM Pentier - The Journal of , 2020 - Am Soc Clin Investighttps://www.jci.org/articles/view/130562 Vaccination with the WT-1 126-134 Peptide in Patients with Acute Myeloid Leukemia after Allogenic Stem Cell Transplantation. C Gentilini, A Letsch , A Asemissen, A Muessig - Blood, 2006 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0006497118451221 Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody C Augsberger , G Hanel, W Xu, V Pulko - Blood, The Journal , 2021 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/138/25/2655/476420 1 WITH AT CELL BISPECIFIC ANTIBODY (WT1-TCB): EX VIVO AND IN VIVO POTENCY BY BIVALENT RECOGNITION OF PEPTIDE-MHC COMPLEXES FROM AN C Augsberger , C Klein , C Heitmuller, W Xu - , 2019 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1097/01.HS9.0000559044.46812.aa Two to tango: engineered T cells against AML C Arber - Blood, 2024 - ashpublications.orghttps://ashpublications.org/blood/article/143/6/476/514777 Gemcitabine/WT1 peptide loaded dendritic cell vaccine A Soeda - Reactions, 2011 - Springerhttps://link.springer.com/article/10.2165/00128415-201113350-00080 INDUCTION OF IMMUNE RESPONSES TO WILMS TUMOR 1 (WT1), A SELF-ANTIGEN, IN MICE A Saint-Fleur - 2014 - jscholarship.library.jhu.eduhttps://jscholarship.library.jhu.edu/bitstream/1774.2/39279/1/SAINT-FLEUR-DISSERTATION-2014.pdf

• Marchio: Biosynth